Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Find out which ETFs consistently pay qualified dividends and how this impacts your tax strategy and after-tax returns.
22,163 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Chord Energy reports strong 2025 results driven by Williston Basin efficiency, but investors question whether this wi...
Investors await Federal Reserve Chair Jerome Powell's remarks as U.S. markets drift higher on rising oil prices. Anal...
Robinhood launches a controlled beta of its new Social feature, inviting a small group of users to follow traders, di...
Argentina’s wine industry faces its sharpest downturn in over a decade, with record-low consumption and thousands of ...
Crypto markets tank $100B in a single session as the Federal Reserve signals a hawkish stance and likely fewer rate c...
Rivian shares surged about 8% after the company unveiled the R2 midsize SUV, signaling a push toward broader market a...
The 2025 ATTOM report shows a sharp slowdown in home flipping activity, with profits slipping to pre-crisis levels as...
A choppy week toppled many growth names, but poet technologies stock sliding captured particular attention. Here’s wh...
The World Gold Council unveiled a blockchain-backed trust layer to link physical gold vaults with digital rails, sign...
Accenture beat on earnings and bookings, but two major firms trimmed price targets as investors weigh AI’s effect on ...
Freshworks unveils a $400 million share repurchase as it shifts to AI-based pricing, prompting investor debate over w...